Perspective Therapeutics, Inc. (NYSE:CATX) Shares Purchased by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC boosted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 37.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,236 shares of the company’s stock after buying an additional 6,000 shares during the period. Trueblood Wealth Management LLC’s holdings in Perspective Therapeutics were worth $71,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new position in shares of Perspective Therapeutics during the 2nd quarter worth $630,000. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the second quarter worth about $117,000. Renaissance Technologies LLC raised its stake in Perspective Therapeutics by 94.2% during the second quarter. Renaissance Technologies LLC now owns 61,660 shares of the company’s stock worth $615,000 after purchasing an additional 29,914 shares during the period. HighVista Strategies LLC purchased a new position in Perspective Therapeutics during the second quarter worth about $1,132,000. Finally, Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics in the 2nd quarter valued at about $3,951,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CATX has been the subject of a number of recent analyst reports. UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer cut their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics has an average rating of “Moderate Buy” and an average target price of $15.14.

Insiders Place Their Bets

In related news, CEO Johan M. Spoor acquired 8,000 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the purchase, the chief executive officer now owns 36,257 shares of the company’s stock, valued at $136,688.89. This represents a 28.31 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at approximately $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 67,570 shares of company stock worth $256,789 over the last 90 days. Corporate insiders own 3.52% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $3.43 on Tuesday. The business has a 50-day moving average of $4.14 and a 200 day moving average of $9.94. Perspective Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million during the quarter. Research analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.